Absci (ABSI) Non-Current Debt (2020 - 2025)
Absci (ABSI) posted Non-Current Debt of $65000.0 for Q3 2025, down 59.63% sequentially from $161000.0 in Q2 2025, and down 96.98% YoY from $2.2 million in Q3 2024.
Absci (ABSI) Non-Current Debt (2020 - 2025) Analysis & Trends
Absci has reported Non-Current Debt for 6 years, with the latest figure at $65000.0 in Q3 2025.
- Quarterly Non-Current Debt fell 96.98% year-over-year to $65000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $65000.0 (down 96.98% YoY) and the FY2024 annual result came in at $1.3 million, down 73.03% from the prior year.
- Non-Current Debt eased to $65000.0 in Q3 2025 per ABSI's latest filing, from $161000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $8.0 million in Q4 2022 and troughed at $65000.0 in Q3 2025.
- A 5-year average of $3.5 million and a median of $3.2 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt soared 1254.05% in 2023, then plunged 96.98% in 2025.
- Over 5 years, Non-Current Debt stood at $1.1 million in 2021, then surged by 610.32% to $8.0 million in 2022, then tumbled by 41.63% to $4.7 million in 2023, then tumbled by 73.03% to $1.3 million in 2024, then tumbled by 94.83% to $65000.0 in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $65000.0, $161000.0, and $682000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 682,000.00 |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 4.66 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 6.38 Mn |
| Mar 31, 2023 | 7.19 Mn |
| Dec 31, 2022 | 7.98 Mn |
| Sep 30, 2022 | 6.52 Mn |
| Jun 30, 2022 | 7.13 Mn |
| Mar 31, 2022 | 531,000.00 |
| Dec 31, 2021 | 1.12 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 3.35 Mn |
| Dec 31, 2020 | 4.14 Mn |